← Back to Clinical Trials
Recruiting NCT06045702

NCT06045702 Establishment of a Primary Epididymal Cell Model From Epididymal Samples to Study CFTR Gene Regulation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06045702
Status Recruiting
Phase
Sponsor University Hospital, Brest
Condition Cystic Fibrosis
Study Type OBSERVATIONAL
Enrollment 20 participants
Start Date 2024-09-11
Primary Completion 2026-09-09

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Epididymal sample

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 20 participants in total. It began in 2024-09-11 with a primary completion date of 2026-09-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this observational study is to better understand the role and involvement of the regulatory elements of the CFTR gene, with the aim of better describing the 3D organisation of chromatin at the CFTR locus in epididymal cells in patients with male infertility of any kind, or with cystic fibrosis or bilateral agenesis of the vas deferens, requiring scheduled surgery. The main questions it aims to answer are: * to better characterise this 3D organisation of the CFTR locus, the study of regulatory elements in primary epididymal cells is the most relevant and realistic model. * to gain a better understanding of the regulation of the CFTR gene in epididymal cells in order to gain a better understanding of the pathology of male infertility caused by bilateral agenesis of the vas deferens, a symptom and also a borderline form of cystic fibrosis. Participants will Epididymal samples will be taken by a urologist for the AMP department during the planned surgery. The rest of the samples taken will be recovered for research purposes, with the aim of recovering the epididymal cells contained in the sample. This is in no way an additional procedure and will have no impact on the patient's health..

Eligibility Criteria

Inclusion Criteria: * Male patients over 18 years of age * Patients, without genetic pathology, scheduled for epididymal sampling surgery * Patients with cystic fibrosis or bilateral vas deferens agenesis, scheduled for epididymal sampling surgery. * Signature of a consent form Exclusion Criteria: * Patients not scheduled for epididymal harvesting surgery * Patients under legal protection (guardianship, curatorship) * Refusal to participate

Contact & Investigator

Central Contact

Antoine VALERI, MD,PhD

✉ Antoine.Valeri@univ-brest.fr

📞 +33298347170

Principal Investigator

Antoine VALERI, MD,PhD

PRINCIPAL INVESTIGATOR

University Hospital, Brest

Frequently Asked Questions

Who can join the NCT06045702 clinical trial?

This trial is open to male participants only, aged 18 Years or older, studying Cystic Fibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06045702 currently recruiting?

Yes, NCT06045702 is actively recruiting participants. Contact the research team at Antoine.Valeri@univ-brest.fr for enrollment information.

Where is the NCT06045702 trial being conducted?

This trial is being conducted at Brest, France.

Who is sponsoring the NCT06045702 clinical trial?

NCT06045702 is sponsored by University Hospital, Brest. The principal investigator is Antoine VALERI, MD,PhD at University Hospital, Brest. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology